To whom it may concern

DNV MEDCERT GmbH
Pilatuspool 2
20355 Hamburg
Germany

Tel: +49 40 2263325-0
E-mail: Medcert-Info@dnv.com

Date:
2023-07-07

Our reference:
QS-2879

Notified Body Confirmation Letter
Certification No: 2879GB454230707

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices

To whom it may concern,

This letter confirms that DNV Medcert GmbH, a Notified Body (NB), designated against Regulation (EU) 2017/745 (MDR) and identified by the number 0482 on Nando[1], has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer.

Meyer-Haake GmbH Medical Innovations
Daimlerstr. 4
61239 Ober-Mörlen
Germany
SRN[2]: DE-MF-000013583

The devices covered by the formal application and the written agreement mentioned above are identified in the tables (in the appendix of this letter). Table 1 identifies the devices for which an MDR application has been received, a written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by 20 March 2023 for the relevant devices.

[1] Nando (New Approach Notified and Designated Organisations) Information System, https://ec.europa.eu/growth/tools-databases/nando/.
[2] Single registration number (SRN) according to Article 31 (2) of MDR.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by EU 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding well established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips, and connectors)
- 31 December 2028 for other Class IIb devices, Class IIa devices, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

For DNV MEDCERT GmbH

Monika Hamann
Manager Customer Service

Appendix (see following pages):

- Table 1 and Table 2
- Revision history

Appendix

Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
Devices for surgery with radiofrequency generator, single-use - other	Class IIb excluding Class IIb implantable non-WET	N/A	Certificate 1 2879DE410180918; NB 0482 Certificate 2 2879GB410180918; NB 0482
Glues	Class IIb excluding Class IIb implantable non-WET	N/A	Certificate 1 2879DE410180918; NB 0482 Certificate 2 2879GB410180918; NB 0482

Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
None	None	None	None

Confirmation Letter Revision History:

Date	NB internal reference traceable to each version of the letter	Action
2023-07-07	2879GB454230707	Initial issue

EG – Konformitätserklärung für Medizinprodukte
Declaration of Conformity of Medical Devices

(nach dem Anhang II der EG-Richtlinie über Medizinprodukte 93/42/EWG)
(in accordance with Annex II of the EU Council Directive 93/42/EEC)

Wir / We	**Meyer-Haake GmbH Medical Innovations Daimlerstr. 4, 61239 Ober-Moerlen / Germany**
erklären in alleiniger Verantwortung, dass die Medizinprodukte	**EPIGLU® - Wundkleber TRUGLUE® - Wundkleber**
declare on our own responsibility that the medical devices	**EPIGLU® - Tissue Adhesive TRUGLUE® - Tissue Adhesive**
GMDN Code / GMDN Code:	**34164**
Artikel-Nr: / Order No.: EPIGLU®:	**EPIGLU1P / EPIGLU2P / EPIGLU4P / EPIGLUSP / EPIGLUOS / EPIGLUSD / EPISDP10 / EPISDP25 / EPIGLSDF / EPISD10F / EPISD25F / EPIGLUBP**
TRUGLUE®:	**EPITRUSD**
EPITRUSD wird verpackt in / EPITRUSD is packaged as:	**75005 / 75006 / 75007**
Klasse / Class	**IIb**

allen Anforderungen der Richtlinie 93/42/EWG Anhang II, entspricht.
meet all the requirements of the Directive 93/42/EEC, Annex II.

Benannte Stelle: / Notified body:	**MEDCERT GmbH Pilatuspool 2 20355 Hamburg/Germany**
Verfahrens-Nr. / Process No.:	**QS 2879**
Bescheinigungs-Nr. Certificate No.:	**2879DE410180918 2879GB410180918**
Identifikations-Nr. / Identification No.:	**0482**
Gültig bis Valid until	**8. Juli 2023 July 8th 2023**

Ober-Moerlen, den 23. Februar 2021

MEYER-HAAKE MEDICAL INNOVATIONS www.meyer-haake.com Daimlerstraße 4 61239 Ober-Mörlen

Meyer-Haake GmbH Medical Innovations
Jürgen Meyer-Haake
Geschäftsführer / Managing Director

Meyer-Haake GmbH
Medical Innovations
Daimlerstraße 4
61239 Ober-Mörlen
Deutschland/Germany

Tel/Phone: +49 (0) 60 02 - 9 92 70 - 0
Fax: +49 (0) 60 02 - 9 92 70 - 22
E-Mail: info@meyer-haake.com
export@meyer-haake.com
Internet: www.meyer-haake.com

Geschäftsführer:
Jürgen Meyer-Haake
Heike Jordan
HRB 7239
AG Friedberg/Hessen

Frankfurter Volksbank eG
Konto-Nr. / Acc. No.: 6 100 860 269
BLZ: 501 900 00
IBAN: DE52 5019 0000 6100 860 269
SWIFT/BIC: FFVBDEFF

Steuer-Nr.:
020 239 40104
UST-ID / VAT-ID-NO.:
DE 814495607